small molecule glp-1 agonist Drug Hunter's 2023 Patent Review of GLP-1R Agonists | Drug Hunter posted on the topic In the ACHIEVE-1 phase 3
Description
A.ChanM.DesaiA
Contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
The letter also detailed prior communications sent by the FDA to the manufacturer about their marketing efforts
Dual GLP-1/GIP receptor agonists (molecules engineered to simultaneously activate GLP-1R and GIPR) represent a pharmacological leap beyond classical incretin-based therapies
Glucagon-like peptide-1 receptor agonists piggyback on this natural pathway by mimicking the glucagon-like peptide-1 hormone
